Navigation Links
Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
Date:10/19/2009

uarter ended September 30, 2009 are scheduled for Monday, November 16, 2009, after the market closes. Encorium will hold a conference call at 11:00 a.m. EST Tuesday, November 17, 2009, to discuss its financial results and corporate developments. Additional details will be forthcoming.

This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process.

This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions. Those
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
2. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
3. Encorium Reports Second Quarter 2009 Financial Results
4. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
5. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
6. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
7. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
8. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
9. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
10. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
11. Encorium Reports Third Quarter 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... like to be able to charge their cell phones and o...n. A recent discovery made by UC San Diego enginee...tors that could do just this. , In recent resea...akar Bandaru, a professor in the UCSD Department o... graduate student Mark Hoefer, have found that art...
(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 ...or in biotechnology for diabetes therapy, and a pr...ices to food, supplement, biotechnology and pharma...previously reported $6.3 million registered direct... shares of its common stock and warrants to purcha...
(Date:11/19/2009)...STER, Germany, November 19 MONITOR...ovember 16th, 2009 Flibanserin in the,indication t...arkinson,s,disease for orphan drug status designat...odopa-induced dyskinesia is a complication of the ...erious burden to some of those,affected, since it ...
(Date:11/19/2009)... InSound is honored by latest award for revolu...wark, CA (PRWEB) November 16, 2009 -- Popular Scie...rdquo; hearing aid from InSound Medical a winner o...e Health category.    Chosen f...side deep in the hearing canal for up to four mont...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
...ate Conference Call and Webcast on March 14 at 8:0...AN DIEGO, March 13 Halozyme Therapeutics,Inc. (Na...ing and,commercializing products targeting the ext...s for the three months and year ended December 31,...ur partnered programs, while,building a strong fou...
...ch 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceu...pecialty pharmaceutical and,medical device company...idated financial statements and Management,s Discu... 2007 and the restatement of its audited,consolida...er 31, 2006., For the year ended December 31, 200...
... Patent Challenge Underway -, CORONA, Calif., Mar... a leading specialty pharmaceutical,company, today...ug,Application (ANDA) with the U.S. Food and Drug ...s Levonorgestrel and Ethinyl Estradiol tablets, US...ive product prior to the,expiration of patents own...
Other Biology Technology:Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 6Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 7Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 8Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 2Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 3Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 4Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 5Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 6Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 7Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 8Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 9Watson Files FDA Application for Generic LYBREL(R) 2
(Date:11/20/2009)...9 - Bacteria possess an ingenious mechanism for pr...f the cell. This is the new finding of a team of b...fe sciences research institute in Flanders, Belgiu...e scientists made this discovery by modifying the .... By means of this model organism, they have uncov...
(Date:11/20/2009)...ary disease (COPD), a respiratory disease commonly...fourth leading cause of death worldwide. 600 mill...ve yet to find any real treatment or cure, Grace P...sity of Western Ontario in London, Canada, is usin...nto the disease. , Parraga is a scientist in...
(Date:11/19/2009)... brain chemical with an unwieldy name: 4-hydroxybu... used as a date-rape drug. , Now, a team of Ohi...es by which 4-HB is metabolized by the body. "This...l Gibson, professor and chair of biological scienc...er of the research team. "It may provide new clue...
Breaking Biology News(10 mins):Biologists discover bacterial defense mechanism against aggressive oxygen 2Gaining a better picture of lung disease 2Researchers begin to decipher metabolism of sexual assault drug 2Florida State Tobacco Tax Increase May Prompt Smokers to Quit Spontaneously 50601 1Florida State Tobacco Tax Increase May Prompt Smokers to Quit Spontaneously 50601 2Florida State Tobacco Tax Increase May Prompt Smokers to Quit Spontaneously 50601 3ISPA Releases 2009 U S Spa Industry Statistics 50596 1ISPA Releases 2009 U S Spa Industry Statistics 50596 2Growth Hormone May Build Muscle in Older Men 50591 1Growth Hormone May Build Muscle in Older Men 50591 2
...s announces the latest addition to its Cumulative ... (Cumitechs) publication series: Cumitech 46 -- L... Parasitic Diseases. , This Cumitech is intended ...d other members of the patient care team in the ap...ests for the diagnosis and management of blood-bor...
...ch team has developed the first small molecule tha...n balancing sodium levels, paving the way for drug...nditions. , The human epithelial sodium channel ...ch as the lungs, kidneys, and colon, and it is vit...essure. Interestingly, while there are available d...
...born in India and Sri Lanka are three times more l...n pregnancy (hyperemesis gravidarum) than ethnic N...nstitute of Public Healths study of 900, 000 first...Registry of Norway over a forty year period. , E...t women experience some degree of nausea and vomit...
Other Biology News:Extreme nausea and vomiting varies among pregnant women from different countries 2
Mouse Anti-Human KRT4 Monoclonal Antibody, Unconjugated, Clone 5H5 from Abnova Corporation
Mouse Anti-Human ARHGEF11 Monoclonal Antibody, Unconjugated, Clone 2F4 from Abnova Corporation
...es ,High Quality, Functionally-Validated, Ion Chan...having a critical role in nerve and muscle functio...S and the heart. Drugs that modulate ion channels ...as neuropathic pain, cardiac arrhythmia, hypertens...
...es ,High Quality, Functionally-Validated, Ion Chan...having a critical role in nerve and muscle functio...S and the heart. Drugs that modulate ion channels ...as neuropathic pain, cardiac arrhythmia, hypertens...
Biology Products: